1. Academic Validation
  2. Discovery and optimization of pyrazole amides as antagonists of CCR1

Discovery and optimization of pyrazole amides as antagonists of CCR1

  • Bioorg Med Chem Lett. 2019 Feb 1;29(3):435-440. doi: 10.1016/j.bmcl.2018.11.015.
Christian Harcken 1 Christopher Sarko 2 Can Mao 2 John Lord 2 Brian Raudenbush 2 Hossein Razavi 2 Pingrong Liu 2 Alan Swinamer 2 Darren Disalvo 2 Thomas Lee 2 Siqi Lin 3 Alison Kukulka 3 Heather Grbic 4 Mita Patel 4 Monica Patel 4 Kim Fletcher 4 David Joseph 4 Della White 5 Laura Amodeo 5 Karen Berg 5 Maryanne Brown 5 David S Thomson 2
Affiliations

Affiliations

  • 1 Medicinal Chemistry Department, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT 06877-0368, USA. Electronic address: [email protected].
  • 2 Medicinal Chemistry Department, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT 06877-0368, USA.
  • 3 Compound Profiling Department, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT 06877-0368, USA.
  • 4 Drug Discovery Support Department, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT 06877-0368, USA.
  • 5 Immunology & Respiratory Disease Research Department, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT 06877-0368, USA.
Abstract

A HTS screen for CCR1 antagonists afforded a novel sub-micromolar hit 5 containing a pyrazole core. In this report the design, optimization, and SAR of novel CCR1 antagonists based on a pyrazole core motif is presented. Optimization led to the advanced candidate compounds (S)-16q and (S)-16r with 250-fold improved CCR1 potency, excellent off-target selectivity and attractive drug-like properties.

Keywords

CCR1; Chemokine receptors; Development candidate; HTS hit; Pyrazole.

Figures
Products